Clinical Research Directory
Browse clinical research sites, groups, and studies.
Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project
Sponsor: University of Miami
Summary
The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.
Official title: Cetirizine Versus Diphenhydramine as a Pre-medication: Tolerability and Safety in Patients With MS Receiving Anti-Cluster of Differentiation 20 (CD20) Infusion Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-07-01
Completion Date
2028-07-01
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
Cetirizine
Participants will receive a single oral dose of cetirizine 10 mg administered 30-60 minutes before the scheduled standard-of-care anti-CD20 infusion at each visit.
Diphenhydramine
Participants will receive a single oral dose of diphenhydramine 50 mg administered 30-60 minutes before the scheduled standard-of-care anti-CD20 infusion at each visit.
Locations (1)
UHealth Boca Raton
Boca Raton, Florida, United States